Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Åpen studie for å evaluere sikkerheten og effekten av CABA-201 hos personer med aktiv idiopatisk inflammatorisk myopati

12. november 2026 oppdatert av: Cabaletta Bio

En fase 1/2, åpen studie for å evaluere sikkerheten og effekten av autologe CD19-spesifikke kimære antigenreseptor-T-celler (CABA-201) hos personer med aktiv idiopatisk inflammatorisk myopati

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Studieoversikt

Detaljert beskrivelse

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Studietype

Intervensjonell

Registrering (Antatt)

74

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • University of California Irvine - Accepting Adult Patients
        • Hovedetterforsker:
          • Tahseen Mozaffar, MD
        • Ta kontakt med:
      • San Francisco, California, Forente stater, 94158
        • Rekruttering
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, Forente stater, 80046
        • Rekruttering
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • Hovedetterforsker:
          • Dr. Kentaro Yomogida, MD
        • Ta kontakt med:
    • Florida
      • Jacksonville, Florida, Forente stater, 32224
        • Rekruttering
        • Mayo Clinic Florida - Accepting Adult Patients
        • Ta kontakt med:
      • St. Petersburg, Florida, Forente stater, 33701
        • Rekruttering
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • Hovedetterforsker:
          • Natalie Booth, DO
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30032
        • Rekruttering
        • Emory University - Accepting Adult Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, Forente stater, 30029
        • Rekruttering
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • Hovedetterforsker:
          • Shanmuganathan Chandrakasan, MD
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • Hovedetterforsker:
          • Dr. George Georges, MD
        • Ta kontakt med:
      • Chicago, Illinois, Forente stater, 60637
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • University of Kansas Medical Center - Accepting Adult Patients
        • Ta kontakt med:
    • Maryland
      • Bethesda, Maryland, Forente stater, 20892
        • Rekruttering
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02115
        • Rekruttering
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • Hovedetterforsker:
          • Susan Prockop, MD
        • Ta kontakt med:
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48105
        • Rekruttering
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55902
        • Rekruttering
        • Mayo Clinic - Accepting Adult Patients
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • David R. Fernandez, MD, PhD
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • Hovedetterforsker:
          • Jae Park, MD
        • Ta kontakt med:
      • The Bronx, New York, Forente stater, 10467
        • Rekruttering
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27599
        • Rekruttering
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • Hovedetterforsker:
          • Saira Sheikh, MD
        • Ta kontakt med:
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • Hovedetterforsker:
          • Kaveh Ardalan, MD, MS
        • Ta kontakt med:
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Rekruttering
        • Oregon Health & Science University - Accepting Adult Patients
        • Ta kontakt med:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, Forente stater, 15261
        • Rekruttering
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • Rekruttering
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • Ta kontakt med:
    • Texas
      • Dallas, Texas, Forente stater, 75390
        • Rekruttering
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • Hovedetterforsker:
          • Samuel John, MD
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Houston Methodist Hospital - Accepting Adult Patients
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • Hovedetterforsker:
          • Huifang (Linda) Lu, MD
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84113
        • Rekruttering
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, Forente stater, 98105
        • Rekruttering
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Har ikke rekruttert ennå
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • Hovedetterforsker:
          • Sara Sabbagh, DO
        • Ta kontakt med:
          • Erin Hammelev - Research Coordinator
          • Telefonnummer: 414-337-7064
          • E-post: ehammele@mcw.edu
      • Roma, Italia, 00165
        • Rekruttering
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Professor Franco Locatelli
      • London, Storbritannia, WC1N 3BG
        • Rekruttering
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr. Pedro Machado, FRCP, PhD
      • London, Storbritannia, SE5 9RS
        • Rekruttering
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, Storbritannia, WC1N 3JH
        • Rekruttering
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Professor Despina Eleftheriou
      • Manchester, Storbritannia, M13 9WL
        • Rekruttering
        • Manchester Royal Infirmary - Accepting Adult Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, Storbritannia, M6 8HD
        • Rekruttering
        • Salford Royal Hospital - Accepting Adult Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
      • Göttingen, Tyskland, 37075
        • Har ikke rekruttert ennå
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr. Jana Zschüntzsch

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 år til 75 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andre navn:
  • Rese-Cel
  • Resecabtagene autoleucel
Eksperimentell: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andre navn:
  • Rese-Cel
  • Resecabtagene autoleucel
Eksperimentell: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andre navn:
  • Rese-Cel
  • Resecabtagene autoleucel

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 1/2: Incidence and severity of adverse events (AEs)
Tidsramme: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events and laboratory abnormalities
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
Tidsramme: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
Tidsramme: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studiestol: Medical Director, Cabaletta Bio

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. desember 2023

Primær fullføring (Antatt)

1. juli 2028

Studiet fullført (Antatt)

1. juli 2028

Datoer for studieregistrering

Først innsendt

16. november 2023

Først innsendt som oppfylte QC-kriteriene

30. november 2023

Først lagt ut (Faktiske)

4. desember 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere